Hepatitis E Virus (HEV) in Makkah, Saudi Arabia: A Population-Based Seroprevalence Study
Viruses · 2023
DOI: 10.3390/v15020484 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Mai M El-Daly und 12 weiteren Autor:innen. Beteiligte Einrichtung: Special Infectious Agents Unit-BSL3, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21362, Saudi Arabia. Hauptthemen laut MEDLINE: Hepatitis E virus. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institutional Fund Projects, Ministry of Education and King Abdulaziz University.
Abstract (Originalsprache)
Background
The Hepatitis E virus (HEV) is a common cause of viral hepatitis worldwide. Little is known about the seroprevalence of HEV in the general population of Saudi Arabia.
Methods
A community-based cross-sectional HEV seroprevalence study was conducted in Makkah, Saudi Arabia. Anti-HEV IgG antibodies were detected in sera using an in-house ELISA. The frequency of HEV sageerology and its correlation with demographic, and environmental factors were evaluated.
Results
Enrollment consisted of 1329 individuals, ages ranged from 8 to 88 years, the mean age was 30.17 years, the median age was 28yrs, and the male: female ratio was 1.15. The overall seroprevalence was 23.8% (316/1329). Males had significantly higher seroprevalence than females (66.1 vs. 33.9%; p < 0.001). Seroprevalence had significant correlations with age, occupation, and lack of regular water supply and housing conditions.
Conclusions
This is the first HEV community-based seroprevalence study from Saudi Arabia. Results show that the HEV is endemic in Makkah and affects all age groups and occupations. HEV affects more males than females and those living in crowded accommodations without a regular supply of water. Further studies are required across all regions of Saudi Arabia to determine the country’s seroprevalence of active or past infection using tests for HEV IgG, HEV IgM antibodies and/or HEV RNA and underlying determinants of transmission.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Special Infectious Agents Unit-BSL3, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21362, Saudi Arabia.
- Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
- Community Medicine Department, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
- Student Research and Innovation Unit, Faculty of Medicine, King Abdulaziz University, Jeddah 21362, Saudi Arabia.
- Ministry of Health, Makkah 24226, Saudi Arabia.
- Ministry of Health, Jeddah 22246, Saudi Arabia.
ORCID-Profile: Mai M El-Daly, Rajaa Al-Raddadi, Omaima I Shabouni, Thamir A Alandijany, Tian-Cheng Li, Sherif A El-Kafrawy, Esam I Azhar
Förderung
- Institutional Fund Projects
- Ministry of Education and King Abdulaziz University
Zitieren
APA
El-Daly, M. M., Al-Raddadi, R., Alharbi, A., Azhar, A. E., Khallaf, A. M., Hassan, A. M., Alwafi, O. M., Shabouni, O. I., Alandijany, T. A., Li, T. C., El-Kafrawy, S. A., Zumla, A., & Azhar, E. I. (2023). Hepatitis E Virus (HEV) in Makkah, Saudi Arabia: A Population-Based Seroprevalence Study. Viruses. https://doi.org/10.3390/v15020484
Vancouver
El-Daly MM, Al-Raddadi R, Alharbi A, Azhar AE, Khallaf AM, Hassan AM, et al. Hepatitis E Virus (HEV) in Makkah, Saudi Arabia: A Population-Based Seroprevalence Study. Viruses. 2023. doi:10.3390/v15020484
BibTeX
@article{ElDaly2023,
author = {El-Daly, Mai M and Al-Raddadi, Rajaa and Alharbi, Amany and Azhar, Abdulrahman E and Khallaf, Amjed M and Hassan, Ahmed M and Alwafi, Osama M and Shabouni, Omaima I and Alandijany, Thamir A and Li, Tian-Cheng and El-Kafrawy, Sherif A and Zumla, Alimuddin and Azhar, Esam I},
title = {Hepatitis E Virus (HEV) in Makkah, Saudi Arabia: A Population-Based Seroprevalence Study},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15020484}
}
EUVIMED